Risk of incumbents matching sensitivity
BillionToOne
This risk is really about whether superior detection stays a product advantage or becomes table stakes. In oncology, the winner is not just the lab that finds more mutations once, but the one that can keep finding clinically useful mutations at scale, get doctors comfortable ordering it, and stack up reimbursement, validation, and workflow advantages before larger rivals close the gap. BillionToOne is still early in that race, while Guardant and Foundation Medicine already have deep clinical footholds.
-
BillionToOne is entering oncology from a much smaller base. It launched liquid biopsy in 2022 and reached $153M estimated 2024 revenue across the company, while Guardant alone reported $737M of 2024 revenue. That scale matters because more volume funds more studies, more sales coverage, and faster assay iteration.
-
Foundation Medicine and Guardant are not starting from zero on sensitivity. FoundationOne Liquid CDx is FDA approved across solid tumors, and Foundation says its assay has high sensitivity at higher ctDNA fractions. Guardant has been expanding its Smart Liquid Biopsy platform and adding new therapy selection applications, which is exactly how a larger rival narrows a detection gap.
-
Even if raw mutation detection converges, incumbents still have distribution advantages. Foundation Medicine sells both tissue and blood based profiling, which fits how oncologists already work, and Guardant has broad commercial adoption in liquid biopsy. That means BillionToOne likely needs to stay clearly better, not just slightly better, to win premium accounts.
The next phase is a shift from proving the assay can detect more, to proving that better detection changes treatment decisions often enough to reshape ordering behavior. If BillionToOne keeps extending its lead, it can carve out high value oncology workflows. If larger rivals match that performance, competition will tilt toward reimbursement, installed relationships, and bundled tissue plus blood testing.